The company did a fine job of boosting sales of numerous drugs.A double beat in its latest quarter made Johnson & Johnson (JNJ 3.69%) stock a popular item on Wednesday. The encouraging (if not spectacular) results pushed the storied healthcare company's share price up by almost 4%, which contrasted positively with the 1.4% slide of the S&P 500 index on the day.Solid growth, particularly in the No. 1 categoryJohnson & Johnson revealed that its second-quarter sales came in at slightly over $22.4 billion, repr ...

Johnson & Johnson's (J&J) MedTech arm displayed resilience in its second quarter, navigating inflationary headwinds while prioritizing innovation. The unit, a key driver for J&J, remains committed to full-year growth targets despite temporary setbacks in its vision care business. Challenges arose from distributor adjustments in the contact lens market, leading to destocking. J&J officials expressed confidence in a swift recovery fueled by its innovation pipeline. This focus on innovative solutions propelled ...

Loading...Loading...Investors loved the Johnson & Johnson JNJ earnings report. The stock is trading much higher, but it has stalled out around an important resistance level.In financial markets, some price levels have more importance than others. As you can see on the chart, the $155.00 has been an important one for JNJ. It has been both a resistance and a support level. That's why it is our Stock of the Day.The stock found support around $155.00 in February before reversing and moving higher. After selling ...

JHVEPhoto I initiated a “Buy” rating for Johnson & Johnson (NYSE:JNJ) in January 2024, highlighting its balanced growth between MedTech and medicine business. The company released its Q2 FY24 results on July 17th, beating the market estimates for both the top line and bottom line. I am encouraged by the company’s strong product pipeline, and the recent acquisition of Shockwave Medical. I reiterate a “Buy” rating with a fair value of $190 per share. Robust Product Pipeline Johnson & Johnson delivered 6. ...

Johnson & Johnson’s (JNJ) second-quarter 2024 earnings came in at $2.82 per share, which beat the Zacks Consensus Estimate of $2.71. Earnings rose 10.2% from the year-ago period.Adjusted earnings exclude intangible amortization and some other special items. Including these items, J&J reported second-quarter earnings of $1.93 per share, down 5.9% year over year.Sales of this drug and medical devices giant came in at $22.45 billion, which beat the Zacks Consensus Estimate of $22.38 billion. Sales rose 4.3% fr ...

Johnson & Johnson (NYSE:JNJ) Q2 2024 Earnings Conference Call July 17, 2024 8:30 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joe Wolk - Executive Vice President, Chief Financial Officer Joaquin Duato - Chairman and Chief Executive Officer Jennifer Taubert - Executive Vice President, Worldwide Chairman, Pharmaceuticals Tim Schmid - Executive Vice President, Worldwide Chairman, MedTech John Reed - Executive Vice President, Innovative Medicine, R&D Conference Call Participants ...

About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...

Johnson & Johnson TodayJNJJohnson & Johnson$155.63 +4.62 (+3.06%) 52-Week Range$143.13▼$175.97Dividend Yield3.19%P/E Ratio9.70Price Target$174.07Add to WatchlistJohnson & Johnson NYSE: JNJ has struggled for the last year or two as the impacts of COVID-19 and the spin-off of Kenvue NYSE: KVUE work their way through the system. The takeaway from the Q2 earnings release is that organic growth is back in the picture. Reported revenue is down compared to last year because of the Kenvue spin-off. Still, the shift ...

Johnson & Johnson (JNJ) reported $22.45 billion in revenue for the quarter ended June 2024, representing a year-over-year decline of 12.1%. EPS of $2.82 for the same period compares to $2.80 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $22.35 billion, representing a surprise of +0.43%. The company delivered an EPS surprise of +4.06%, with the consensus EPS estimate being $2.71.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall ...

Key TakeawaysJohnson & Johnson on Wednesday reported second-quarter earnings with sales topping estimates.However, profits fell short of projections thanks to one-time costs like legal fees and asset amortization.The company lifted its full-year sales guidance, while also lowering profit estimates. Johnson & Johnson (JNJ) reported mixed second-quarter results Wednesday, as one-time costs caused the company to miss profit estimates despite better-than-expected sales. Sales of the company's pharmaceuticals an ...